Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1 by Lai, Y.-C. et al.
Phosphoproteomic screening identifies Rab GTPases as
novel downstream targets of PINK1
Y.-C. Lai, C. Kondapalli, R. Lehneck, J. B. Procter, B. D. Dill, H. I.
Woodroof, R. Gourlay, M. Peggie, T. J. Macartney, O. Corti, et al.
To cite this version:
Y.-C. Lai, C. Kondapalli, R. Lehneck, J. B. Procter, B. D. Dill, et al.. Phosphoproteomic
screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO Journal,
EMBO Press, 2015, 34 (22), pp.2840-2861. <10.15252/embj.201591593>. <hal-01285599>
HAL Id: hal-01285599
http://hal.upmc.fr/hal-01285599
Submitted on 9 Mar 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution 4.0 International License
Resource
Phosphoproteomic screening identifies Rab
GTPases as novel downstream targets of PINK1
Yu-Chiang Lai1,†, Chandana Kondapalli1,†, Ronny Lehneck2, James B Procter3, Brian D Dill1,
Helen I Woodroof1, Robert Gourlay1, Mark Peggie4, Thomas J Macartney4, Olga Corti5,6,7,8,
Jean-Christophe Corvol5,6,7,8,9,10, David G Campbell1, Aymelt Itzen2, Matthias Trost1,* &
Miratul MK Muqit1,11,**
Abstract
Mutations in the PTEN-induced kinase 1 (PINK1) are causative of
autosomal recessive Parkinson’s disease (PD). We have previously
reported that PINK1 is activated by mitochondrial depolarisation
and phosphorylates serine 65 (Ser65) of the ubiquitin ligase Parkin
and ubiquitin to stimulate Parkin E3 ligase activity. Here, we have
employed quantitative phosphoproteomics to search for novel
PINK1-dependent phosphorylation targets in HEK (human embry-
onic kidney) 293 cells stimulated by mitochondrial depolarisation.
This led to the identification of 14,213 phosphosites from 4,499
gene products. Whilst most phosphosites were unaffected, we
strikingly observed three members of a sub-family of Rab GTPases
namely Rab8A, 8B and 13 that are all phosphorylated at the highly
conserved residue of serine 111 (Ser111) in response to PINK1
activation. Using phospho-specific antibodies raised against Ser111
of each of the Rabs, we demonstrate that Rab Ser111 phosphoryla-
tion occurs specifically in response to PINK1 activation and is
abolished in HeLa PINK1 knockout cells and mutant PINK1 PD
patient-derived fibroblasts stimulated by mitochondrial depolari-
sation. We provide evidence that Rab8A GTPase Ser111 phosphory-
lation is not directly regulated by PINK1 in vitro and demonstrate
in cells the time course of Ser111 phosphorylation of Rab8A, 8B and
13 is markedly delayed compared to phosphorylation of Parkin at
Ser65. We further show mechanistically that phosphorylation at
Ser111 significantly impairs Rab8A activation by its cognate
guanine nucleotide exchange factor (GEF), Rabin8 (by using the
Ser111Glu phosphorylation mimic). These findings provide the first
evidence that PINK1 is able to regulate the phosphorylation of Rab
GTPases and indicate that monitoring phosphorylation of Rab8A/
8B/13 at Ser111 may represent novel biomarkers of PINK1 activity
in vivo. Our findings also suggest that disruption of Rab GTPase-
mediated signalling may represent a major mechanism in the
neurodegenerative cascade of Parkinson’s disease.
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Introduction
Human mutations in genes encoding the mitochondrial protein
kinase, PTEN-induced kinase 1 (PINK1), and the ubiquitin E3 ligase,
Parkin, are associated with autosomal recessive Parkinson’s disease
(PD) (Kitada et al, 1998; Valente et al, 2004). There is accumulating
evidence that these enzymes operate in a common signalling path-
way that regulates mitochondrial quality control (Kazlauskaite &
Muqit, 2015; Koyano & Matsuda, 2015; Pickrell & Youle, 2015).
Genetic analysis in Drosophila melanogaster revealed that PINK1
and Parkin null flies exhibit significant mitochondrial defects and
that PINK1 lies genetically upstream of Parkin (Clark et al, 2006;
Park et al, 2006). In mammalian cells, PINK1 is activated in
response to mitochondrial depolarisation and this stimulates
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the recruitment of Parkin, a cytosolic protein, to depolarised
mitochondria where it ubiquitylates multiple mitochondrial
substrates to trigger the removal of mitochondria by autophagy (also
known as mitophagy; Narendra et al, 2008, 2010; Geisler et al, 2010;
Matsuda et al, 2010; Vives-Bauza et al, 2010). We and other groups
have found that upon activation, PINK1 directly phosphorylates
Parkin at serine 65 (Ser65) within its ubiquitin-like (Ubl) domain
(Kondapalli et al, 2012; Shiba-Fukushima et al, 2012) and ubiquitin
at an equivalent Ser65 residue (Kane et al, 2014; Kazlauskaite et al,
2014b, 2015; Koyano et al, 2014), and together, phosphorylation of
both residues leads to maximal recruitment and activation of Parkin
at mitochondria (Kane et al, 2014; Kazlauskaite et al, 2014a,b, 2015;
Koyano et al, 2014; Ordureau et al, 2014).
The molecular interplay of PINK1 and Parkin in a common path-
way fits seamlessly with clinical observations that PD patients with
PINK1 and Parkin mutations have similar phenotypes (Khan et al,
2002). However, the existence of additional PINK1-dependent
phosphorylation sites has been suggested from the analysis of rat
knockout models of PINK1 and Parkin (Dave et al, 2014). PINK1
knockout rats exhibited progressive neurodegeneration, whereas
Parkin knockout rats remained unaffected, suggesting that PINK1
may regulate additional proteins that are essential for neuronal
integrity and survival in the mammalian brain (Dave et al, 2014).
Furthermore, over recent years, several genetic interactors of PINK1
have been identified in Drosophila models that can rescue the loss
of function phenotype of PINK1 null but not Parkin null flies (e.g.
TRAP1), suggesting that PINK1 downstream signalling may in part
be distinct from Parkin (Zhang et al, 2013).
PINK1 is imported to mitochondria where its levels are kept low
due to constitutive cleavage by mitochondrial proteases (Jin et al,
2010; Deas et al, 2011; Meissner et al, 2011) and proteasomal degra-
dation via the N-end rule pathway (Yamano & Youle, 2013).
However, upon mitochondrial depolarisation that can be artificially
induced by mitochondrial uncoupling agents such as carbonyl
cyanide m-chlorophenyl hydrazone (CCCP), PINK1 import via the
TOM40 and TIM23 complexes is blocked and PINK1 is able to
escape proteolytic cleavage and accumulate at the outer mitochon-
drial membrane (OMM) (Narendra et al, 2010) where it becomes
catalytically active as judged by PINK1 autophosphorylation and
phosphorylation of substrates (Kondapalli et al, 2012; Okatsu et al,
2012).
Under conditions in which PINK1 is stabilised and activated in
mammalian cell lines, we have exploited advances in affinity-based
methods for isolation of phosphopeptides combined with quantita-
tive mass spectrometry to undertake a systematic analysis of PINK1-
dependent phosphorylation sites in membrane-enriched fractions
that contain mitochondria and associated compartments (e.g. endo-
plasmic reticulum) in which PINK1 signalling has been implicated.
This excitingly revealed a novel role for PINK1 in the regulation of
Rab GTPases.
Rab GTPases play a major role in endocytic and vesicle traf-
ficking and are critical for neuronal function (Ng & Tang, 2008).
However, to date, there is little known in relation to Rab GTPases
and PINK1-dependent neurodegeneration. We therefore decided to
further investigate the phosphorylation of Rab GTPases in response
to PINK1 activation.
Our analysis reveals that PINK1 regulates the phosphorylation of
a highly conserved residue, serine 111 (Ser111), of a family of Rab
GTPases, namely Rab8A, 8B and 13. Using phospho-specific anti-
bodies raised against phospho-Ser111 for each of the Rab GTPases,
we demonstrate that Rab Ser111 phosphorylation is abolished in
PINK1 knockout as well as PINK1 mutant patient-derived cells,
indicating that this site is absolutely dependent on PINK1. We
provide evidence that PINK1 may not directly phosphorylate these
Rabs and instead may regulate an intermediate kinase and/or
phosphatase that targets Rab Ser111 for phosphorylation. To obtain
molecular insights into the impact of phosphorylation on Rab
GTPase function, we have purified a Ser111-phosphomimetic of
Rab8A. We demonstrate that the addition of a negative charge
significantly impairs interaction with and activation by its cognate
guanine exchange factor (GEF), Rabin8. Our findings provide funda-
mental new knowledge on the regulation of Rab GTPases by PINK1
and suggest that monitoring Rab Ser111 phosphorylation would
represent a novel biomarker of PINK1 activity in vivo. Furthermore,
our findings suggest that Rab GTPases may represent a molecular
nexus between the PINK1 signalling pathway and other PD-linked
genes.
Results
SILAC-based PINK1 phosphoproteomic screen
We and other groups have previously reported that the Parkinson’s
associated PINK1 kinase becomes activated in mammalian cells
upon mitochondrial depolarisation that can be induced by mitochon-
drial uncouplers such as CCCP (Kondapalli et al, 2012; Okatsu et al,
2012). This leads to phosphorylation of its substrates Parkin and
ubiquitin at the equivalent residue Ser65 (Kondapalli et al, 2012;
Kane et al, 2014; Kazlauskaite et al, 2014b; Koyano et al, 2014;
Ordureau et al, 2014). To identify novel PINK1-dependent phospho-
rylation targets, we undertook a quantitative phosphoproteomic
screen using stable isotope labelling by amino acids in cell culture
(SILAC). Human Flp-In T-Rex HEK293 cells stably expressing empty-
FLAG vector control, kinase-inactive (KI) D384A PINK1-FLAG, or
wild-type human PINK1-FLAG were grown in “light” (R0, K0),
“medium” (R6, K4) and “heavy” (R10, K8) SILAC media, respec-
tively, for a minimum of five passages (Fig 1A). Labelling efficiency
was assessed and found to be > 95 % across all four biological
replicates (data not shown). Cells were treated with CCCP (10 lM
for 3 h) to stimulate PINK1 catalytic activity, and membrane-
enriched mitochondrial containing fractions were made by ultracen-
trifugation and then solubilised in 1% RapiGest. Protein amounts
were determined, and equivalent wild-type and kinase-inactive
PINK1 expression/stabilisation by CCCP was confirmed in each
replicate by immunoblotting (Fig 1B). Cell lysates from the three dif-
ferent conditions were combined in a 1:1:1 ratio. Protein extracts
were reduced, cysteines alkylated and digested using trypsin
(Fig 1A). Digested peptides from each replicate were subjected to
fractionation by hydrophilic interaction liquid chromatography
(HILIC; McNulty & Annan, 2008), and 15 fractions were collected per
experiment (Appendix Fig S1). Each fraction was further subjected
to phosphopeptide enrichment using TiO2 spin columns before anal-
ysis by mass spectrometry (Larsen et al, 2005; Trost et al, 2009;
Fig 1A). Scatter plot analysis demonstrated a high level of repro-
ducibility across all replicates (Appendix Fig S2).
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Figure 1. SILAC phosphoproteomic approach for the identification of PINK1-dependent targets.
A Illustration of SILAC phosphoproteomics workflow. Flp-In T-Rex HEK293 cells stably expressing FLAG alone were cultured in unlabelled (R0K0) medium, kinase-inactive
(KI; D384A) PINK1-FLAG cells were “medium” (R6K4) labelled, and wild-type (WT) PINK1-FLAG cells were “heavy” (R10K8) labelled using SILAC media containing the
respective isotopes. All conditions were treated with 10 lM CCCP for 3 h and subjected to membrane fractionation. Four biological replicates of the samples were
mixed in a 1:1:1 ratio, digested and fractionated by HILIC. Phosphopeptides from these fractions were enriched by TiO2 chromatography and analysed by quantitative
mass spectrometry on an Orbitrap Velos Pro mass spectrometer. Data were analysed by MaxQuant and Perseus software packages.
B About 25 lg of membrane-enriched lysate from the mass spectrometry experiments was immunoblotted with anti-PINK1 antibody. TOMM40 and GAPDH serve as
markers for mitochondria and cytoplasm, respectively.
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Altogether, 52 samples were separated on a 50 cm × 75 lm
online reversed-phase column and analysed on an Orbitrap Velos Pro
using 4 h gradients. This led to the identification of 14,213 phospho-
sites (FDR < 1%) from 4,499 gene products among which 12,374
were quantified (Table EV1). Volcano and frequency plot analyses
of wild-type PINK1 versus kinase-inactive PINK1 (WT/KI; H/M)
revealed that whilst most of these phosphosites remained unaffected
(Fig 2A, Appendix Fig S3A), 34 phosphosites increased significantly
(P < 0.05, > 3-fold) (Table EV2, Fig EV1A and B) and 7 phospho-
sites decreased significantly (WT/KI; H/M)) (P < 0.05, < 0.33-fold)
(Table EV3). Comparative analysis revealed 16 of these phospho-
sites were also increased significantly when comparing wild-type
PINK1 versus empty vector (P < 0.05, > 3-fold; WT/vector; H/L)
(Appendix Fig S3B).
In validation of the screen, we detected a 24-fold increase,
between WT and KI conditions, of a previously reported Thr257
PINK1 autophosphorylation site (VALAGEYGAVpTYR; Figs 2A and
EV1C, and Table EV2; Kondapalli et al, 2012). We also observed a
significant 17-fold increase in the ubiquitin Ser65 phosphopeptide
that we have already reported last year together with other groups
as a direct PINK1 substrate (Figs 2A and EV1C, and Table EV2;
Kazlauskaite et al, 2014b).
Strikingly among the most highly changing phosphopeptides
detected, were peptides corresponding to an equivalent phosphory-
lation site, Ser111, of three closely related Rab GTPases, namely
Rab8A, 8B and 13 that were up-regulated 21-, 30- and 50-fold,
respectively, between WT and KI conditions across all 4 replicates
(Figs 2A and EV1C, Table EV2 and Appendix Fig S4). Further-
more, we also detected a 6-fold increase in an equivalent Ser114/
111 (Ser114/111) phosphopeptide of Rab1A/1B (Fig 2A, Table EV2).
Multiple sequence alignment of the region surrounding Ser111 of
Rab8A, 8B and 13 revealed that these were highly conserved
across all species (Fig 2B). Moreover, across the different Rab
GTPases, there was strong conservation of surrounding residues
with an Ala at the 1 position, an acidic Glu residue at the 3
position and Val and Glu at the + 3 and + 4 positions, respectively
(Fig 2B).
Validation that PINK1 regulates phosphorylation of Ser111 of
Rab GTPases
To confirm that PINK1 can regulate the phosphorylation of Ser111
of Rab GTPases in cells, we over-expressed full-length human
N-terminal HA-tagged Rab8A, Rab8B and Rab13 in Flp-In T-Rex
HEK293 cells stably expressing wild-type human PINK1, or kinase-
inactive PINK1 (Fig 3A–C). Cells were stimulated with or without
CCCP for 3 h and Rab8A/8B/13 extracts immunoprecipitated with
HA agarose, and phosphorylation site analysis performed by mass
spectrometry. Consistent with the phosphoproteomic screen, this
analysis revealed that Rab8A, 8B and 13 were phosphorylated at
Ser111 but only in cells expressing wild-type PINK1 that had been
stimulated with CCCP (Fig 3A–C and Appendix Figs S5–S7). In
contrast, no detectable phosphorylation of Ser111 was detected
in the absence of CCCP stimulation or in cells expressing kinase-
inactive PINK1 (Fig 3A–C and Appendix Figs S5–S7).
We next raised phospho-specific antibodies that specifically
recognise Rab8A, 8B and 13 phosphorylated at Ser111 (see Materials
and Methods) and assessed phosphorylation in Flp-In T-Rex
HEK293 cells stably expressing wild-type or kinase-inactive PINK1
that were transfected with HA-Rab8A, 8B or 13. Extracts were
subjected to immunoprecipitation with HA agarose followed by
immunoblotting with each phospho-specific antibody, and we were
able to confirm that over-expressed Rab8A, 8B and 13 (Fig 3D)
phosphorylations were induced, following the stimulation of wild-
type but not kinase-inactive PINK1-expressing cells upon treatment
with CCCP. Furthermore, mutation of Ser111 to Ala abolished the
recognition of phospho-Rab8A, 8B and 13 in CCCP-treated cells
over-expressing wild-type PINK1, confirming the specificities of the
antibodies generated (Fig 3D).
PINK1 activation is essential for Rab8A, 8B and 13 Ser111
phosphorylation in cells
We next investigated whether endogenous PINK1 is sufficient and
necessary for phosphorylation of Rab8A, 8B and 13 Ser111 in cells
upon activation induced by CCCP-induced mitochondrial depolarisa-
tion. Wild-type HA-Rab8A, 8B and 13 as well as the corresponding
non-phosphorylatable S111A mutant of each Rab GTPase was
expressed in both wild-type and PINK1 knockout HeLa cells gener-
ated by CRISPR/Cas9 technology (Narendra et al, 2013). Cells were
treated with 10 lM CCCP or DMSO for 20 h, and lysates were
subjected to HA agarose immunoprecipitation followed by
immunoblotting with the anti-phospho-Rab Ser111 antibody. We
observed phosphorylation of wild-type but not S111A HA-Rab8A,
HA-Rab8B and HA-Rab13 in cells stimulated with CCCP, and impor-
tantly, this phosphorylation was abolished in the PINK1 knockout
cells (Fig 4A). Furthermore, to demonstrate that the loss of Rab
Ser111 phosphorylation was specifically due to PINK1 knockout and
not an off-target effect of CRISPR/Cas9 generation, we re-expressed
wild-type PINK1-3xFLAG or kinase-inactive (D384A) PINK1 into the
knockout cells and we observed rescue of Rab8A, 8B and 13 Ser111
phosphorylation only upon expression of wild-type but not kinase-
inactive PINK1 (Fig 4A).
To further validate the physiological regulation of Rab GTPase
Ser111 by PINK1, we next determined whether endogenous PINK1,
upon activation, was capable of phosphorylating endogenous
levels of Rab8A. Wild-type and PINK1 knockout HeLa cells were
stimulated with CCCP, and lysates were subjected to immuno-
precipitation using a Rab8A antibody followed by immunoblotting
of immunoprecipitates with either anti-phospho-Rab Ser111 or total
Rab8A antibodies. This revealed that endogenous Rab8A Ser111
phosphorylation occurred in wild-type but not in PINK1 knockout
Hela cells stimulated with CCCP to induce PINK1 activation
(Fig 4B). Furthermore, phosphorylation of Rab8A was rescued by
re-expression of wild-type but not kinase-inactive PINK1 (Fig 4B).
We also obtained similar results in HEK293 cells (Appendix Fig S8).
These results confirm that endogenous PINK1 can regulate endoge-
nous Rab8A Ser111 phosphorylation in cells.
Rab8A Ser111 phosphorylation is abolished in human
PINK1 patient-derived fibroblasts and mouse PINK1
knockout fibroblasts
To explore the physiological relevance of PINK1-dependent Rab
GTPase Ser111 phosphorylation to Parkinson’s disease (PD), we next
analysed primary human fibroblasts derived from a patient with PD
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Figure 2. Analysis of PINK1-regulated phosphoproteome and identification of Ser111 phosphopeptides of Rab GTPases.
A Volcano plot highlighting significantly (P < 0.05, > three-fold change) up-regulated (red) and down-regulated (green) phosphopeptides identified in each screen. Rab
GTPases are marked in purple.
B Sequence alignment of Ser111 phosphorylation site in Rab8A, Rab8B and Rab13 orthologs from mammals to Drosophila shows high conservation around the Ser111
phosphorylation site (blue asterisk).
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bearing the homozygous Q456X mutation and an unaffected
individual from the same family (see Materials and Methods). Using
recombinant insect PINK1 in vitro kinase assays, we have previ-
ously demonstrated that the Q456X mutation completely abolishes
the catalytic activity of PINK1 via truncation of the C-terminal
region that is essential for kinase function (Woodroof et al, 2011).
After stimulation of fibroblasts with CCCP, lysates were subjected to
Rab8A immunoprecipitation followed by immunoblotting of
immunoprecipitates with either anti-phospho-Rab Ser111 or total
Rab8A antibodies. We observed total loss of Rab8A Ser111 phospho-
rylation in PINK1 Q456X fibroblasts following CCCP treatment
(Fig 5A). In comparison, we detected robust phosphorylation of
Rab8A Ser111 in control human fibroblasts associated with stabilisa-
tion of full-length PINK1 after CCCP treatment (Fig 5A).
Since the Rab8A Ser111 site and surrounding residues are highly
conserved between human and mouse (Fig 2B), we next investi-
gated Rab8A Ser111 phosphorylation in a PINK1 knockout mouse
model (Gandhi et al, 2009). Mouse embryonic fibroblasts (MEFs)
were generated from PINK1 knockout or wild-type littermate control
mice (see Materials and Methods) and stimulated with CCCP.
Immunoprecipitation–immunoblot analysis revealed Rab8A Ser111
phosphorylation in wild-type but not in PINK1 knockout MEFs after
stimulation with CCCP (Fig 5B), consistent with our analysis in
human PINK1 knockout HeLa cells (Fig 4B).
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Figure 3. Rab8A, Rab8B and Rab13 Ser111 phosphorylations are regulated by PINK1 upon CCCP treatment.
A–C Confirmation by mass spectrometry that Rab8A (A), Rab8B (B) and Rab13 (C) Ser111 is phosphorylated upon PINK1 activation after CCCP treatment. Flp-In T-Rex
HEK293 cells expressing empty-FLAG, WT PINK1-FLAG and KI (D384A) PINK1-FLAG were transfected either with HA-Rab8A (A), HA-Rab8B (B) or HA-Rab13 (C)
induced with doxycycline and stimulated with 10 lM of CCCP for 3 h. Whole-cell lysates (10 mg) were immunoprecipitated with anti-HA agarose, resolved by
SDS–PAGE and stained with colloidal Coomassie blue (second panel). Coomassie-stained bands migrating with expected molecular mass of HA-Rabs were excised,
in-gel digested with trypsin and subjected to high-performance liquid chromatography with LC-MS/MS on an LTQ-Orbitrap mass spectrometer. Upper panel shows
the extracted ion chromatogram (XIC) analysis of Ser111-containing phosphopeptides (8A, NIEEHApSADVEK; 8B, NIEEHApSSDVER; 13, SIKENApSAGVER) with the
combined signal intensity of the 2+ and 3+ forms of the peptide indicated on the y-axis. Note that the Ser111 phosphopeptide was only detected in samples from
WT PINK1-FLAG-expressing cells following CCCP stimulation.
D Characterisation of Rab8A, Rab8B and Rab13 phospho-Ser111 antibodies. Flp-In T-Rex HEK293 cells expressing empty-FLAG, WT PINK1-FLAG and KI (D384A) PINK1-
FLAG were transfected with either WT or Ser111Ala-mutant (S111A) HA-Rab8A, HA-Rab8B or HA-Rab13, induced with doxycycline and stimulated with 10 lM of
CCCP for 3 h. Whole-cell lysates (0.25 mg) were immunoprecipitated with anti-HA agarose and immunoblotted with Rab8A, Rab8B or Rab13 phospho-Ser111
antibodies. Part of the immunoprecipitates was used to immunoblot for HA antibody as loading controls.
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Rab8A is not required for PINK1-dependent activation of Parkin
E3 ligase activity
The demonstration that PINK1 can phosphorylate Rab8A Ser111 in
wild-type HeLa cells (that lack detectable Parkin) suggests that
Parkin is not required for PINK1-targeting of Rab8A (Fig 4A and B).
We further confirmed this in MEFs derived from a Parkin knockout
mouse model (Itier et al, 2003) (see Materials and Methods).
Immunoprecipitation–immunoblot analysis revealed Rab8A Ser111
phosphorylation in both wild-type and Parkin knockout MEFs after
stimulation with CCCP (Appendix Fig S9A and B).
Conversely to investigate whether PINK1-dependent targeting
and activation of Parkin was dependent on Rab8A, we over-
expressed full-length wild-type (WT) or catalytically inactive
Cys431Phe (C431F) Parkin in wild-type HeLa cells or Rab8A knock-
out HeLa cells generated by CRISPR/Cas9 technology (see Materials
and Methods; Fig 6). Cells were treated with or without CCCP for
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A PINK1 is essential for CCCP-mediated Rab8A Ser111 phosphorylation. WT
and PINK1 KO HeLa cells were transfected with either WT or Ser111Ala
(S111A) mutant constructs of HA-Rab8A, HA-Rab8B or HA-Rab13. Some
PINK1 KO HeLa cells were reintroduced with PINK1 by transfection of WT
PINK1-3xFLAG or KI (D384A) PINK1-3xFLAG as indicated. After transfection
for at least 24 h, cells were treated with DMSO as a vehicle control or CCCP
for 20 h. Whole-cell lysates (1 mg) were immunoprecipitated with anti-HA
agarose and immunoblotted with Rab8A, Rab8B or Rab13 phospho-Ser111
antibody. Part of the immunoprecipitates was used to immunoblot for HA
antibody as loading controls. For the lower panel, whole-cell lysates (30 lg)
were immunoblotted with total PINK1 antibody to confirm PINK1
expression and with GAPDH as loading controls.
B Endogenous Rab8A Ser111 phosphorylation is PINK1 dependent. WT and
PINK1 KO HeLa cells were treated with DMSO as a vehicle control or CCCP
for 20 h. Some PINK1 KO HeLa cells were reintroduced with PINK1 by
transfection of WT PINK1-3xFLAG or KI (D384A) PINK1-3xFLAG as indicated
for at least 24 h before CCCP treatment. Whole-cell lysates (1 mg) were
immunoprecipitated with anti-Rab8A pre-bound with protein A agarose
followed by immunoblot with Rab8A phospho-Ser111 antibody. Part of the
immunoprecipitates was used to immunoblot with anti-total Rab8A
antibody as loading controls.
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Figure 5. Rab8A Ser111 phosphorylation is abolished in Parkinson’s
disease patient PINK1 fibroblasts and PINK1 knockout mouse embryonic
fibroblasts (MEFs).
A Absence of Rab8A Ser111 phosphorylation in human mutant PINK1 patient
fibroblasts. Primary skin fibroblasts were derived from a patient with
homozygous PINK1 Q456X mutation or unaffected control. Cells were
incubated with DMSO or CCCP for 20 h, and whole-cell lysates (1 mg) were
immunoprecipitated with anti-Rab8A antibody conjugated to protein A
agarose and immunoblotted with total or Rab8A phospho-Ser111 antibody.
Lysates (1 mg) were also subjected to immunoprecipitation with polyclonal
anti-PINK1 antibody and immunoblotted with monoclonal PINK1 antibody.
Equal loading of protein extracts was confirmed by GAPDH.
B Absence of Rab8A Ser111 phosphorylation in PINK1 knockout MEFs. MEFs
were derived from PINK1 knockout embryos or wild-type controls (see
Materials and Methods). Cells were incubated with DMSO or CCCP for 20 h,
and whole-cell lysates (1 mg) were immunoprecipitated with anti-Rab8A
antibody conjugated to protein A agarose and immunoblotted with total or
Rab8A phospho-Ser111 antibody. Lysates (1 mg) were also subjected to
immunoprecipitation with a polyclonal anti-mouse-specific PINK1 antibody
and immunoblotted with a different anti-mouse-specific PINK1 antibody.
Equal loading of protein extracts was confirmed by GAPDH.
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6 h—conditions that induce stabilisation and activation of PINK1
and Rab8A phosphorylation (Fig 6). We assessed ubiquitylation of
two previously reported Parkin substrates, CISD1 and mitofusin 2
(Sarraf et al, 2013), by immunoblotting mitochondrial extracts
enriched for ubiquitylated proteins using immobilised haloalkane
dehalogenase (HALO)-tagged UBAUBQLN1 technology which prefer-
entially binds all types of poly-ubiquitin chains (Fig 6). In wild-type
HeLa cells, expressing WT but not C431F Parkin, we observed
multi-monoubiquitylation of CISD1 after CCCP treatment indicative
of Parkin activation and this was unaffected in Rab8A knockout
cells (Fig 6). Similarly, we did not observe any difference in
mitofusin 2 ubiquitylation between wild-type and Rab8A knockout
cells (Fig 6). Interestingly, we observed residual ubiquitylation of
mitofusin 2 in HeLa cells expressing C431F Parkin upon CCCP
stimulation, suggesting that additional E3 ligases may be activated
by CCCP and contribute to mitofusin 2 ubiquitylation. In future
work, it will be interesting to determine whether this Parkin-
independent E3 ligase activity is PINK1 dependent.
Evidence that PINK1 does not directly phosphorylate
Rab8A Ser111
We next investigated whether PINK1 could directly phosphorylate
Rabs at Ser111. Sequence alignment of the Rab8A, 8B and 13 Ser111
site and Rab1A/B Ser114/111 with the phosphorylatable residue Ser65
of Parkin and ubiquitin did not reveal significant sequence similarity
(Fig EV2A). It has recently been suggested that the structural fold
rather than the sequence may be the determining factor for PINK1
recognition of direct substrates (Wauer et al, 2015). Consistent with
this, we have found that PINK1 is unable to phosphorylate a peptide
bearing Ser65 of the Parkin Ubl domain (Fig EV2B).
We therefore undertook a comparative analysis of structural data
available on the location of the phosphorylatable residues: ubiquitin
Ser65, Parkin Ser65, Rab8A Ser111 and the paralogous Rab1A Ser114.
Inspection of their structural environment (Fig 7A) demonstrates
that the phosphorylated sites in ubiquitin and Parkin have a mark-
edly different structural environment to those of Rab8A and Rab1A.
In both ubiquitin and Parkin, the phosphorylated serine lies after a
right-handed b-turn, before the 5th b-strand. In contrast, the phos-
phoserine of Rab8A and Rab1A occurs after a C-terminal helix cap
and before a right-handed b-turn. The different conformations
adopted by these sites suggest that distinct kinases are involved in
the phosphorylation of the two groups (Fig 7A).
We next tested this prediction in phosphorylation assays of
full-length untagged Rab8A with catalytically active recombinant
wild-type or kinase-inactive Tribolium castaneum PINK1 (TcPINK1).
In contrast to ubiquitin, we observed only weak phosphorylation of
Rab8A by TcPINK1 with a maximal stoichiometry of approximately
0.03 moles of 32P-phosphate per mole of protein (Fig 7B). Further-
more, mutation of Ser111 to Ala did not prevent phosphorylation of
Rab8A by TcPINK1, indicating that Ser111 is not directly phosphory-
lated by PINK1 (Fig 7B). To identify the sites of Rab8A phosphory-
lated by TcPINK1 in vitro, 32P-labelled Rab8A was digested with
trypsin and separated by reversed-phase chromatography on a C18
column. This revealed two major 32P-labelled peptides, and a
combination of solid-phase Edman sequencing and mass spectrome-
try revealed that each corresponded to a peptide phosphorylated at
Thr74 and Thr72, respectively (Fig EV2C–E). We did not observe
any evidence by mass spectrometry that these Thr sites are regu-
lated by PINK1 in cells upon stimulation with CCCP under condi-
tions in which we do observe Ser111 phosphorylation, suggesting
that they may not be relevant in vivo (data not shown).
Timecourse of Rab8A Ser111 phosphorylation
Using Flp-In T-Rex HEK293 cells stably expressing wild-type PINK1,
we have previously reported that PINK1 is activated at 5 min as
judged by monitoring Parkin Ser65 phosphorylation (Kondapalli
et al, 2012). Under similar conditions, we next investigated the
phosphorylation of Rab8A, 8B and 13 Ser111 relative to Parkin Ser65
phosphorylation. Cells were transfected with wild-type Rab8A, 8B,
13 or Parkin and their non-phosphorylatable Ser111Ala (S111A) or
Ser65Ala (S65A) mutants, respectively. Using a phospho-specific
antibody against phospho-Ser65, we observed Parkin Ser65 phospho-
rylation at 5 min as previously reported (Fig 8A) (Kondapalli et al,
2012). In contrast, the phosphorylation of Rab8A, 8B and 13
Ser111 occurred significantly later at ~40 min increasing in a time-
dependent fashion to 3 h (Fig 8A). The delay in Rab Ser111
phosphorylation after PINK1 that becomes active at 5 min strongly
suggests that PINK1 may not directly phosphorylate Rab GTPase
Mitofusin2
CISD1
10 µM CCCP (6 h)
WT
+ +–
50
25
75
U
BA
M
ito
ch
on
dr
ia
l l
ys
at
es
Immunoblot
–
15
Rab8A KO
PARKIN W
T
C4
31
F
37
20
15
+ +– –
W
T
C4
31
F
W
T
C4
31
F
W
T
C4
31
F
U
B
Q
LN
1 p
ul
l d
ow
n
20
25
37
CISD1
HSP60
50
150
100
75 Mitofusin2
50
Ly
sa
te
Parkin
25 Rab8A
CISD1-Ub
Mitofusin2-Ub
CISD1-Ub
PINK1
75
pS111 Rab8A
N.S.25
Figure 6. Rab8A is not required for the activation of Parkin E3 ligase
activity at mitochondria in response to PINK1 activation by CCCP.
Wild-type (WT) or Rab8A knockout (KO) HeLa cells were transfected with WT or
Cys431Phe (C341F)-mutant Parkin. After transfection for 24 h, cells were treated
with DMSO as a vehicle control or 10 lM CCCP for 6 h. Mitochondrial enriched
extracts (mitochondrial lysate) were incubated with ubiquitin-binding resins
derived from his-halo-ubiquilin1 UBA domain tetramer (UBAUBQLN1). Captured
ubiquitylated proteins were subject to immunoblotting with anti-CISD1 and
anti-mitofusin 2 antibodies. Mitochondrial lysate and total lysate were also
subjected to immunoblotting with indicated antibodies for loading and protein
expression controls. Phospho-Ser111 Rab8A was detected after Rab8A
immunoprecipitation from 200 lg of mitochondrial lysate with anti-Rab8A
antibody.
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Ser111 in cells and instead may regulate a kinase or phosphatase
upstream of Rab Ser111 consistent with our in vitro analysis
(Fig 7B).
We next investigated the timecourse of endogenous PINK1 activa-
tion and Parkin Ser65 and Rab Ser111 phosphorylation in HeLa cells.
HeLa cells were transfected in parallel with either wild-type Parkin
or Rab8A, 8B and 13 together with their non-phosphorylatable
Ser65Ala and Ser111Ala mutants, respectively. Using a phospho-
specific antibody against phospho-Ser65, we observed Parkin Ser65
phosphorylation occurring within 10–20 min and becoming maximal
at 1 h upon treatment with CCCP (Fig 8B). In contrast, under
the same conditions, the phosphorylation of Rab8A, 8B and 13 Ser111
occurred significantly later after 1 h of treatment with CCCP
and increased up to 9 h (Fig 8B). Consistent with our PINK1 over-
expression analysis, these results suggest that endogenous PINK1
does not directly phosphorylate Rab at Ser111.
Phosphorylation of Rab8A Ser111 impairs Rabin8-catalysed
GDP exchange
Rab GTPases belong to the superfamily of Ras GTPases and func-
tion as molecular switches cycling between GDP-bound inactive
and GTP-bound active states (Hutagalung & Novick, 2011). To
exert their function, Rabs first require to be activated in a reaction
requiring guanine nucleotide exchange factors (GEFs). GEFs
physiologically catalyse the release of GDP, thereby allowing Rab
activation by binding of GTP, which enables interaction with
effector proteins that bind with high affinity to Rabs in their GTP-
bound but not GDP-bound state. We have previously structurally
defined the interactions of Rab8A with its GEF Rabin8 (Guo et al,
2013). Rabin8 is a 460 amino acid protein that contains a central
Sec2 coiled-coiled domain exhibiting GEF activity towards Rab8
(Hattula et al, 2002). Whilst inspection of the co-crystal structure
of Rab8A and Rabin8 revealed that Ser111 is not directly involved
in the formation of the interface of Rab8A and Rabin8, the side
chain of Ser111 lies close to a negative surface patch of Rabin8
adjacent to the interaction interface (Fig 9A). We therefore hypo-
thesised that the addition of a negative charge on Ser111 may
influence the Rab8A–Rabin8 interaction.
In view of the current challenges in chemical biology technolo-
gies to generate recombinant site-targeted phosphoproteins, we
employed a Ser111Glu (S111E) phosphomimetic of Rab8A to
obtain insights into the molecular consequences of Rab8A Ser111
phosphorylation. Using a previously described homologous co-
chaperone expression system (Bleimling et al, 2009), we expressed
and purified wild-type, S111E and S111A versions of Rab8A to
homogeneity (Appendix Fig S10A). Thermal shift assay analysis
revealed close to identical melting points for wild-type (57.9°C for 1
and 10 lg), S111E (58.0°C for 1 lg and 58.5°C for 10 lg) and
S111A (57.9°C for 1 lg and 57.4°C for 10 lg) Rab8A, suggesting
that Ser111 mutants did not significantly impair protein stability
(Appendix Fig S10B).
In order to analyse the Rab8A–Rabin8 interaction, we utilised a
Rabin8 catalytic assay to quantitatively determine the catalytic
efficiencies (kcat/KM) of Rabin8-stimulated nucleotide release from
wild-type Rab8A or the S111E phosphomimetic mutant (Guo et al,
2013). We preparatively loaded Rab8A with the fluorescent
GDP analogue mantGDP and monitored the Rabin8-catalysed
time-dependent displacement of mantGDP in the presence of excess
GDP as judged by the decrease in mant fluorescence (Fig 9B). Strik-
ingly, we found that the S111E phosphomimetic (kcat/KM =
7.6 × 103 M1s1) but not a S111A mutant (kcat/KM = 8.7
× 104 M1s1) led to a 13-fold decrease in GDP dissociation rate
induced by Rabin8 compared to wild-type Rab8A (kcat/KM = 1.0 ×
105 M1s1) where the kcat/KM is calculated by dividing the rate
constant (kobs) of the reaction by the enzyme concentration (Fig 9B).
We further investigated whether Rab8A Ser111 phosphorylation
could affect GTP hydrolysis since Ser111 lies close to the functionally
important switch II region in the tertiary structure (but not the
primary structure; Fig EV3A). Using reversed-phase HPLC
quantification to monitor GTP-to-GDP conversion over time, we did
not observe any significant difference in the intrinsic GTP hydrolysis
rate between wild-type and the S111E mutant of Rab8A
(kcat(wt) = 2.8 × 10
5 s1, kcat(S111E) = 1.9 × 10
5 s1; Fig EV3B).
In addition, we determined whether Rab8A Ser111 phosphorylation
impacts on the ability of active Rab8A (loaded with the non-
hydrolysable GTP-analogue GppNHp) to bind with known effectors
such as OCRL1 (Hou et al, 2011). Using analytical size-exclusion
chromatography, the S111E phosphomimetic mutant was still able to
form a stable complex with OCRL1539–901 as well as wild-type Rab8A
under these experimental conditions (Fig EV3C). Finally, we tested
whether Rab8A Ser111 phosphorylation may also influence the inter-
action with and de-activation by GTPase-activating proteins (GAPs).
Since there is currently no known Rab8A-GAP that has been
rigorously characterised in biochemical detail, we have exploited the
known Rab promiscuity of the TBC domain of RabGAPs (Frasa et al,
2012). We have therefore expressed a TBC domain containing
fragment of the Rab1-GAP TBC1D20 (residues 1–305; TBC1D201–305)
and confirmed that it possesses Rab8A-GAP activity in vitro
(Fig EV3D) (Sklan et al, 2007). Similarly, the S111E phospho-
mimetic mutants exhibited TBC1D201–305-stimulated GTP hydrolysis
indistinguishable from wild-type Rab8A (Fig EV3D). This suggests
that Ser111 phosphorylation of Rab8A may not lead to a disruption in
Rab8A:GAP interaction as that observed for Rab8A:GEF interaction
(Fig 9B).
Overall, our analysis has revealed that phosphorylation of Rab8A
at Ser111 critically affects Rabin8 catalysis in vitro that would be
predicted to impair Rab8A activation. In future work, it will be criti-
cal to confirm these findings using preparative phosphorylated
Rab8A once the identity of the upstream kinase is elucidated or
alternatively using recently described orthogonal aminoacyl-tRNA
synthetase and tRNA pairs to direct incorporation of phosphoserine
into recombinant Rab GTPase proteins (Rogerson et al, 2015).
Evidence that Rab8A Ser111 phosphorylation disrupts Rabin8
interaction in cells
We next addressed whether phosphorylation of Rab8A at Ser111
influenced the interaction of Rab8A and Rabin8 in cells. We
expressed wild-type (WT) HA-Rab8A, a phosphomimetic S111E
mutant and a S111A mutant of HA-Rab8A in HeLa Rab8A knockout
cells. Lysates were subjected to immunoprecipitation using HA
agarose followed by immunoblotting of immunoprecipitates with
anti-Rabin8 antibody, and we observed co-immunoprecipitation of
endogenous Rabin8 with WT HA-Rab8A (Fig 9C). In contrast, we
observed a drastic reduction in binding of Rabin8 with S111E but
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Figure 7. Evidence that Rab8A Ser111 is not a direct substrate of PINK1.
A Ubiquitin, Parkin, Rab8A and Rab1A phosphosites adopt two distinct conformations. Ser65 in ubiquitin (blue) and Parkin (magenta) follows a b-turn, before the start of
the 5th b-strand. Conversely, Ser114 in Rab1A (green) and Ser111 in Rab8A (ochre) lie after a C-terminal helix cap just before the start of a b-turn. Representative three-
dimensional structures are superimposed by C-a positions for the observed phosphosites and their sequence neighbours. Side chains for observed sites are shown as
sticks, and ribbons depict backbone and secondary structure. To highlight the local environment, regions more than 3 amino acids away from the phosphosites are
made transparent (see Materials and Methods for PDB IDs).
B In vitro phosphorylation analysis of Rab8A by PINK1. WT or S111A-mutant Rab8A (1.2 lg) was incubated in the presence of MBP-fused WT or KI (D359A) TcPINK1
(1.1 lg) and Mg2+-[c-32P] ATP for the indicated time. Samples were subjected to SDS–PAGE, and proteins were detected by colloidal Coomassie blue staining (lower
panel). The [c-32P] incorporation to substrate was detected by autoradiography (upper panel). Cerenkov counting was used to calculate the stoichiometry of substrate
phosphorylation as mol of [c-32P] incorporation/mol of substrate. Ubiquitin was used as a positive control of the TcPINK1 substrate.
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not with S111A Rab8A (Fig 9C). In parallel, co-immunoprecipitation
analyses in which we co-expressed GFP-Rabin8 with either WT,
S111E or S111A HA-Rab8A, we observed the converse that immuno-
precipitation of Rabin8 with GFP binder sepharose resin was associ-
ated with markedly reduced binding of HA-Rab8A S111E to Rabin8
compared to WT and S111A HA-Rab8A (Fig EV4).
Overall, these cellular studies suggest that Rab8A and Rabin8 can
form a complex in cells and that phosphorylation of Rab8A at Ser111
impacts on its interaction with Rabin8 and this provides physiologi-
cal relevance to our in vitro analysis.
Bioinformatic analysis of Rab8A–Rabin8 surface
patch interactions
The negative surface patch of Rabin8 adjacent to the Rab8A
interaction interface is comprised of residues Asp203 (D203),
Glu208 (E208), Glu210 (E210), Glu211 (E211) (Guo et al, 2013).
Given the functional relationship between Rab8A Ser111 phospho-
rylation and the Rabin8 negative patch, it is tempting to specu-
late that this interaction may have co-evolved with PINK1. Were
that the case, then for orthologues of Rab8 and Rabin8 in
organisms that lack PINK1, the interaction between the charged
patch and Ser111 would not need to be conserved. To explore
this hypothesis, we examined proteins orthologous to Rab8 and
Rabin8 in yeast.
We first verified that yeast lacks PINK1. Examination of the entry
for PINK1 in the EggNOG (Powell et al, 2014) orthologue database
suggests PINK1 is only found in metazoans. We also employed the
EggNOG hidden Markov model for PINK1 to search the NCBI NR
protein sequence database with the EMBL-EBI HMMER3 server
(Mistry et al, 2013). No significant matches were found in Saccha-
romyces (data not shown).
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Figure 8. Time-course analysis of Rab8A, Rab8B and Rab13 Ser111 phosphorylation.
A Time-course comparison of PINK1-mediated Rab8A, Rab8B and Rab13 Ser111 phosphorylation vs. Parkin Ser65 phosphorylation. Flp-In T-Rex HEK293 cells expressing WT
PINK1-FLAG were transfected with either WT or Ser111Ala-(S111A) mutant HA-Rab8A, HA-Rab8B or HA-Rab13, induced with doxycycline and stimulated with CCCP for
the indicated time. In parallel, Flp-In T-Rex HEK293 cells expressing WT PINK1-FLAG were transfected with either WT or Ser65 Ala (S65A)-mutant Parkin. Whole-cell
lysates (0.25 mg) were immunoprecipitated with anti-HA agarose and immunoblotted with indicated phospho-Ser111 antibodies. Part of the immunoprecipitates was
used to immunoblot for HA antibody as loading controls. For the lower panel, whole-cell lysates (30 lg) were immunoblotted with indicated antibodies.
B Time-course comparison of endogenous PINK1-mediated Rab8A, Rab8B and Rab13 Ser111 phosphorylation vs. Parkin Ser65 phosphorylation. HeLa cells were
transfected with either WT or S111A-mutant HA-Rab8A, HA-Rab8B or HA-Rab13 for at least 24 h before CCCP treatment for the indicated time. Whole-cell lysates
(1 mg) were immunoprecipitated with anti-HA agarose and immunoblotted with indicated phospho-Ser111 antibodies. In parallel, HeLa cells were transfected with
either WT or S65A-mutant Parkin and whole-cell lysates (30 lg) were immunoblotted with indicated antibodies.
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We then compared Rab8 to Ypt1 and Sec4, its close homologues
in yeast. Multiple sequence alignment of Ypt1, Sec4 and Rab8A
showed that whilst these sequences align well, Rab8A Ser111 is
neither conserved in Ypt1 nor in Sec4 (Fig EV5A). The loop contain-
ing Ser111 in Rab8A is not similar to that of Sec4, but in Ypt1, the
corresponding residue is a threonine, followed by a serine. Struc-
tural data for Ypt1 and Rab8A demonstrate that they exhibit a high
degree of structural homology, and it is probable that Ser112
(Ser112) of Ypt1 would be targeted in a PINK1-independent manner
(Fig EV5A).
Finally, we investigated whether the charged patch in Rabin8 is
conserved and interacts in the same way with Rab8 homologues in
yeast. Sequence alignment of Rabin8 and its yeast orthologue, Sec2,
suggested that the residues forming the charged patch in Rabin8
(D203, E208, E210 and E211) are conserved in Sec2 (Fig EV5B).
However, in Sec2, the patch residues follow an insertion of 14
amino acids, suggesting there may be structural differences between
Sec2 and Rabin8 in this region. We therefore determined whether
the charged patch in Sec2 is oriented in the same way as Rabin8 by
analysing structural data on Rab8A and Sec4 with their respective
exchange factors. Three PDB structures were aligned by matching
chains corresponding to Sec4 (PDB code 2OCY; yeast crystal struc-
ture) and Rab8 (PDB code 4LHY; human crystal structure) to the
Ypt1 chain (PDB code 2BCG; yeast crystal structure). 3D superposi-
tion strikingly revealed that whilst they are similar molecules,
Rabin8 and Sec2 adopt markedly different conformations when
interacting with their respective GTPases (Fig EV5C). Importantly,
the curvature of Sec2’s coiled coil is greater than that of Rabin8, and
therefore, the distance between residue D95 in Sec2 and the putative
YPT1 Ser112 phosphosite is greater than that between the homolo-
gous residue D203 of Rabin8 and Rab8 Ser111 (Fig EV5C). These dif-
ferences suggest that the charged residues in Sec2 and Rabin8 do
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Figure 9. Rab8A Ser111 phosphorylation impairs Rabin8-catalysed GDP exchange in vitro and Rabin8 interaction in cells.
A Crystal structure of Rab8A in complex with guanine exchange factor (GEF) Rabin8 (Guo et al, 2013). Left panel: Rabin8 is shown in surface representation and Rab8A
in cartoon representation. Right panel: Rabin8 is shown in cartoon representation, and Rab8A is shown in surface representation. The hydroxyl group of residue Ser111
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B Rabin8-catalysed mant-GDP release from mant-GDP loaded WT, S111A and S111E mutants of Rab8A. The Rab proteins (1 lM) were incubated with 100 lM GDP in
buffer (20 mM HEPES pH 7.5, 50 mM NaCl, 1 mM MgCl2, 2 mM DTE), and the reaction was started by the addition of 0.5 lM Rabin8. The decrease in mant
fluorescence was used as a measure of mantGDP release.
C Rab8A Ser111 phosphorylation impairs Rabin8 interaction in cells. Rab8A KO HeLa cells were transfected with wild-type (WT), S111E or S111A HA-Rab8A. Whole-cell
lysates (1 mg) were immunoprecipitated with anti-HA agarose and immunoblotted with Rabin8 or anti-HA antibody. Lysates were immunoblotted with Rabin8 or
anti-HA antibody to confirm equivalent expression of Rabin8 and WT and mutant HA-Rab8A in extracts.
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not interact with their corresponding GTPases in the same way,
which may be the result of coevolution in the presence of, or the
lack of PINK1 and the as yet to be identified kinase. Confirmation of
this, however, will involve rigorous phylogenetic analysis of the
GEF superfamily, which is beyond the scope of this current study.
Discussion
Using state-of-the-art subcellular phosphoproteomics (Trost et al,
2010), we have made the fundamental discovery that PINK1 upon
activation by mitochondrial depolarisation regulates a family of Rab
GTPases, Rab8A, 8B and 13 via phosphorylation of a highly
conserved residue Ser111. Furthermore, biochemical and cell-based
analysis of Rab8A suggests that phosphorylation at Ser111 would
impair interaction with its cognate guanine exchange factor (GEF),
thereby preventing its activation (Figs 9 and 10).
Akin to other small GTPases, Rab GTPases cycle between active
GTP-bound and inactive GDP-bound state that differ mainly by the
conformation of two guanine nucleotide binding loops known as
switch I and switch II regions (Hutagalung & Novick, 2011). In the
Rab8–Rabin8 complex, there is a direct interaction of the switch II
region with the GEF that is a universal feature of all currently
known GTPase–GEF complexes (Guo et al, 2013). There are addi-
tional sites of interaction of the switch I region with Rabin8 that
have also been reported for other GTPase–GEF complexes (Guo
et al, 2013). However, there is little known about the influence of
residues that lie outside these direct interfaces of interaction. Our
observation that the addition of a negative charge to Ser111 (that lies
close to but distinct from the Rab8 switch II-Rabin8 interface)
impairs the interaction represents a novel level of regulation of the
GTPase–GEF interaction (Fig 9). In future work, it will be important
to analyse preparatively phosphorylated Ser111 Rab8 to determine
the effect on Rab8–Rabin8 interaction. Furthermore, structural anal-
ysis of the Ser111-phosphorylated Rab8 combined with modelling
studies in the presence or absence of Rabin8 may reveal the mecha-
nism of how phosphorylation alters the Rab8–Rabin8 complex.
The region in which Ser111 lies is known as a complementarity
determining region (CDR) or also a Rab subfamily motif 3 (RabSF3)
that roughly comprise the a3-b5 loop (Ostermeier & Brunger, 1999;
Pereira-Leal & Seabra, 2000). In previous structures of Rab GTPases
in complex with their effectors, the CDR/RabSF3 has been found to
be in contact with the effector, for example the Rab3a–Rabphilin
structure (Ostermeier & Brunger, 1999). CDRs may determine how
some but not all effector proteins can specifically recognise and bind
to one Rab sub-family in the GTP-bound state but not another
(Ostermeier & Brunger, 1999). Rab GTPases are unique among small
GTPases for the significant degree of complexity among their effec-
tors (Wandinger-Ness & Zerial, 2014). For example, OCRL1 is able
to interact with multiple and diverse Rab GTPases including Rab5A,
Rab31, Rab35, Rab6A, Rab8A and Rab8B (Wandinger-Ness & Zerial,
2014). The CDR/RabSF3 is not required for OCRL1 binding to
Rab GTPases (Hou et al, 2011), and consistent with this, we
observed no impact of a Ser111Glu phosphomimetic of Rab8A on
OCRL1539–901 binding by gel filtration complex analysis (Fig EV3C).
It may be that phosphorylation at Ser111 within the CDR/RabSF3
may influence the interaction of Rab8A, 8B and 13 with as yet
unknown effector proteins and it would be exciting in future studies
to identify these and assess their role downstream of PINK1
activation induced by mitochondrial depolarisation.
Previously, only Rab7 together with its Rab GAPs TBC1D15 and
TBC1D17 has been implicated downstream of PINK1 and has been
demonstrated to be required for Parkin-mediated autophagosome
formation and encapsulation of mitochondria during mitophagy
(Yamano et al, 2014). However, our data indicate that PINK1-
regulated phosphorylation of Rab GTPase Ser111 is independent of
Parkin since we observed robust phosphorylation of Rab8A in HeLa
cells that lack endogenous Parkin. This suggests that PINK1 upon
activation may control additional physiological processes distinct
from mitophagy. Over the last few years, PINK1 has been implicated
in the regulation of mitochondrial dynamics (Poole et al, 2008; Yang
et al, 2008; Lutz et al, 2009), mitochondrial motility (Weihofen
et al, 2009; Wang et al, 2011; Liu et al, 2012), and the generation of
mitochondrial derived vesicles that selectively remove damaged
mitochondrial cargos (Sugiura et al, 2014). Very little is known on
the Rab machinery that regulates mitochondrial function and traf-
ficking. In mammalian cells, Rab32 has been found to participate in
mitochondrial dynamics and modulate mitochondria-associated
membrane (MAM) properties (Alto et al, 2002; Bui et al, 2010),
whilst Rab26 has been reported to mediate trafficking between mito-
chondria to the lysosome (Jin & Mills, 2014). Previously, Rab8A, 8B
and 13 have been localised to recycling endosomes, vesicles, and
early endosomes (Wandinger-Ness & Zerial, 2014), and in future
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Figure 10. Schematic representation of PINK1 regulation of Rab8A
Ser111 phosphorylation.
Uponmitochondrial depolarisation, PINK1 activation leads either to activation of
a kinase or to inhibition of a protein phosphatase that targets Ser111
phosphorylation of Rab8A. Phosphorylation of Rab8A at Ser111 impairs Rabin8
(GEF)-mediated GDP exchange leading to GDP-bound inactive Rab8A.
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work, it will be interesting to investigate whether they are required
for mitochondrial trafficking and whether this requirement is funda-
mentally dependent on PINK1 via Ser111 phosphorylation.
Our data suggest that PINK1 does not directly phosphorylate
Ser111 of Rab8A, 8B and 13, suggesting that PINK1 may regulate an
intermediate kinase or phosphatase that directly targets these Rab
GTPases. To date, there has been very little reported on how phos-
phorylation of Rab GTPases alters their function. Recently, Rab5A
was found to be phosphorylated by protein kinase Ce at Thr7 and
this is required for Rac 1 activation, actin rearrangement, and T-cell
motility (Ong et al, 2014). However, large-scale phosphoproteomic
studies have identified multiple phosphorylation sites on Rab
GTPases, suggesting that this may represent an important layer of
regulation to their function. For example, Rab8A has previously
been found to be phosphorylated on residues, Tyr5, Ser17, Thr72,
Tyr77, Tyr78, Ser132, Thr164, Ser181, Ser185 and Thr192 as well as
Ser111;however, the functional effects of phosphorylation of these
sites are unknown (Olsen et al, 2010; Kettenbach et al, 2011;
Shiromizu et al, 2013; Zhou et al, 2013; Bian et al, 2014; Sharma
et al, 2014; Palacios-Moreno et al, 2015). These sites span the entire
Rab GTPase protein affecting key residues required for guanine
nucleotide binding, magnesium ion coordination and GTP hydroly-
sis as well as interaction with GEFs, GAPs and effector molecules. It
will be vital to identify the upstream kinase of Ser111 as well as for
these other sites and investigate how phosphorylation modifies Rab
GTPase function and whether there is any interaction between
phosphorylation events on the same Rab protein. In our screen, we
identified phosphopeptides for the protein kinases ICK and BRSK2
that were up-regulated 3.8- and 3.5-fold, respectively (WT/KI; H/M)
(Fig EV1B, Table EV2), and in future work, it would be exciting to
test whether these kinases directly target Rab GTPases at Ser111.
Multiple sequence alignment of all 66 human Rab GTPases
reveals that 15 share a serine or threonine residue at the equivalent
position of Ser111 of Rab8A within the CDR region (Appendix
Fig S11). In future work, it would be interesting to determine
whether the serine/threonine residue equivalent to Ser111 of these
additional Rabs can be phosphorylated and whether these are
regulated by PINK1 in cells.
A major question in the field is whether PINK1-dependent
pathways are linked to pathways mediated by other PD-linked
genes. Pathologically, Parkinson’s is defined by the presence of
cytoplasmic inclusions known as Lewy bodies whose major
protein component is a-synuclein. Post-mortem analysis of brains
from a family with Parkinsonism harbouring PINK1 mutations
has confirmed the presence of Lewy bodies in the substantia
nigra (Samaranch et al, 2010). Furthermore, there is genetic
evidence of an interaction of a-synuclein and PINK1 since mutant
a-synuclein-linked pathology is exacerbated by genetic loss of
PINK1 in both C. elegans and transgenic mouse models (Kamp
et al, 2010; Chen et al, 2015). However, the molecular link
between a-synuclein and PINK1 has to date remained mysterious.
Previously, a-synuclein over-expression in primary rat neurons
has been demonstrated to disrupt vesicular trafficking and this
can be rescued by over-expression of Rab8A and related Rab
GTPases (Gitler et al, 2008); therefore, the disruption of Rab
GTPases and their downstream signalling pathway could repre-
sent a common pathway mediating PINK1 and a-synuclein-linked
neurodegeneration. Furthermore, human mutations were recently
reported in the RAB39B gene in a family with an X-linked
heritable Parkinsonian syndrome (Wilson et al, 2014) and there is
now strong evidence from genome wide association studies that
variation in the RAB7L locus confers significant risk to the devel-
opment of sporadic PD (Nalls et al, 2014). Recently, LRRK2 has
been implicated in the regulation of Rab GTPases. LRRK2 was
found to interact with Rab7L1 to maintain retromer complex func-
tion and protein sorting (MacLeod et al, 2013). Mutant LRRK2
expressed in cell lines or in PD patient fibroblasts has also been
reported to impair late endosomal trafficking via decreasing Rab7
activity in cells (Gomez-Suaga et al, 2014). Using two structurally
distinct LRRK2 kinase inhibitors (Choi et al, 2012; Reith et al,
2012), we did not find any evidence that LRRK2 regulates Rab8A
Ser111 phosphorylation (Appendix Fig S12). Nevertheless, our
analysis adds to an emerging picture that aberrant signalling of
Rab GTPases may act as a downstream nexus for multiple
genes and their corresponding pathways linked to PD-related
neurodegeneration.
Our phosphoproteomic screen has also identified additional
phosphopeptides that were significantly up-regulated by PINK1
including EFHD2 and FKBP38 that were increased 7.4-fold and 13.6-
fold, respectively, across all four replicates (Figs 2A and EV1B and C,
and Table EV2). EFHD2 is a calcium-binding adaptor protein that
has been found to be associated with pathologically aggregated tau
in the neurodegenerative brain in Alzheimer’s disease and in a
mouse model of frontotemporal dementia (Ferrer-Acosta et al,
2013b). To date, no study has linked EFHD2 with PD. Multiple
sequence alignment of EFHD2 showed that the identified phospho-
site, serine 74, is highly conserved among several species (data not
shown) and lies within the N-terminal region of EFHD2 that may be
important for regulating calcium-binding activity (Ferrer-Acosta
et al, 2013a). FKBP38 is a membrane chaperone predominantly
localised in mitochondria. It was recently reported that FKBP38
translocates from mitochondria to the endoplasmic reticulum during
mitophagy and this escape is essential for suppression of apoptosis
during mitophagy (Saita et al, 2013). The up-regulated phosphopep-
tide of FKBP38 identified in our screen lies close to the C-terminus
of FKBP38 that is essential for its escape (Saita et al, 2013). In future
work, it will be exciting to validate these phosphosites and assess
how PINK1-dependent phosphorylation of these proteins alters their
function and how this is linked to downstream PINK1 signalling.
Overall, our studies have identified a critical role of PINK1 in the
regulation of the phosphorylation of Rab GTPases at Ser111 and
outline a novel signalling pathway for PINK1 independent of Parkin.
GEFs are required for the activation of Rab GTPases, and our analy-
sis indicates that phosphorylation would impair the activation of
Rab GTPases by their cognate GEF. Our study lays the foundation
for future work to uncover the identity of the upstream kinase medi-
ating Rab Ser111 phosphorylation as well as validating other poten-
tial targets that we have uncovered in our comprehensive analysis
of PINK1-dependent proteins. Our findings should also stimulate
general interest in understanding how Rab GTPases are regulated by
protein phosphorylation. Our results strongly suggest that further
understanding of the biological consequences of disruption of Rab
GTPases will illuminate new fundamental mechanisms underlying
Parkinson’s. Our results also indicate that monitoring Rab8A/8B/13
Ser111 phosphorylation represents a novel biomarker for PINK1
activity and may have clinical utility as a biomarker in PD.
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Materials and Methods
Reagents
Tissue culture reagents were from Life Technologies. [c-32P] ATP
was from PerkinElmer. All mutagenesis was carried out using the
QuikChange site-directed mutagenesis method (Stratagene) with
KOD polymerase (Novagen). All DNA constructs were verified by
DNA sequencing, which was performed by The Sequencing Service,
School of Life Sciences, University of Dundee, using DYEnamic
ET terminator chemistry (Amersham Biosciences) on Applied
Biosystems automated DNA sequencers. DNA for mammalian cell
transfection was amplified in E. coli DH5a strain, and plasmid
preparation was done using Qiagen Maxi prep Kit according to the
manufacturer’s protocol. All cDNA plasmids and antibodies gener-
ated for this study are available to request through our reagents
website (https://mrcppureagents.dundee.ac.uk/). All other reagents
and chemicals were standard grade from Sigma or as indicated.
Antibodies
The following antibodies were raised by the Division of Signal Trans-
duction Therapy (DSTT) at the University of Dundee in sheep and
affinity-purified against the indicated antigens: anti-Rab8A phospho-
Ser111 (S503D, 4th bleed; raised against residues 104–117 of human
Rab8A: RNIEEHApSADVEKMR); anti-Rab8B phospho-Ser111 (S504D,
5th bleed; raised against residues 104–117 of human Rab8B: RNIEE-
HApSSDVERMR); anti-Rab13 phospho-Ser111 (S505D, 8th bleed;
raised against residues 104–117 of human Rab13: KSIKENApSAG-
VERLR); anti-total PINK1 (for immunoprecipitation) (S774C, 3rd
bleed; raised against residues 235–end of mouse PINK1); anti-total
PINK1 (for immunoprecipitation–immunoblotting) (S086D, 3rd bleed;
raised against residues 175–250 of mouse PINK1), anti-total Parkin
(for immunoprecipitation) (S328D, 5th bleed; raised against full-
length recombinant GST-mouse Parkin); anti-total PINK1 (for
immunoprecipitation) (S460C) as previously described (Kondapalli
et al, 2012); and anti-GFP antibody (S268B, 1st bleed). The mouse
monoclonal anti-PINK1 antibody (human PINK1 residues 125–539)
was raised by Dundee Cell Products. Anti-Rab8A (for Rab8A specific
immunoprecipitation), anti-Hsp60 and anti-GAPDH antibodies were
obtained from Cell Signalling Technology. Anti-Rab8 (for
immunoblotting) and anti-HA agarose bead were obtained from
Sigma. GFP binder sepharose beads were generated by the DSTT.
Anti-Parkin mouse monoclonal antibody was obtained from Santa
Cruz. Anti-CISD1 and anti-Rabin8 (Rab3IP) antibodies were obtained
from Proteintech. The rabbit monoclonal (NIAR164) anti-mitofusin 2
antibody was obtained from Abcam. Anti-HA HRP antibody was
obtained from Roche. Anti-Parkin phospho-Ser65 rabbit monoclonal
antibody was raised by Epitomics in collaboration with the Michael J
Fox Foundation for Research. Anti-LRRK2 and anti-LRRK2 phospho-
Ser935 antibodies were obtained from Dario Alessi (Dundee).
Cell culture
Flp-In T-Rex HEK293 cells stably expressing FLAG empty, PINK1-
FLAG kinase-inactive (KI) or PINK1-FLAG wild-type (WT) were
generated previously (Kondapalli et al, 2012). CRISPR/Cas9 system-
generated PINK1 knock out (KO) HeLa cells were kindly provided by
Richard Youle (NIH). Flp-In T-Rex HEK293 cells stably expressing
GFP-LRRK2 were provided by Professor Dario Alessi (University of
Dundee, UK) and have been described (Dzamko et al, 2010). Cells
were cultured in DMEM (Dulbeco’s modified Eagle’s medium) supple-
mented with 10% (v/v) foetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin and 0.1 mg/ml streptomycin at 37°C under a
5% CO2 atmosphere. MEF and HeLa cells were maintained using
DMEM plus 1% (v/v) non-essential amino acid. Flp-In T-Rex HEK293
cells were maintained using DMEM plus 15 lg/ml of blasticidin and
100 lg/ml of hygromycin. To express protein in Flp-In T-Rex
HEK293 cells, 0.1 lg/ml of doxycycline was added to the medium
for 24 h. Cell transfections were performed using polyethylenimine
(Polysciences) or Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s instruction. To uncouple mitochondria, cells
were treated with 10 lM CCCP (carbonyl cyanide m-chlorophenyl-
hydrazone) dissolved in DMSO for the indicated times.
Primary human skin fibroblasts
Primary skin fibroblasts at low passage numbers (3–5) were contrib-
uted by the DNA and Cell Bank of the Institut du Cerveau et de la
Moelle e´pinie`re (ICM), Hoˆpital de la Pitie´-Salpeˆtrie`re, Paris, France.
They were obtained from skin biopsies from patients with PD and
age-matched healthy individuals following routine clinical proce-
dures, underwritten informed consent and approval by a local ethics
committee (Comite´ de Protection des Personnes “Ile de France”).
Patients were screened for PARK2 and PINK1 mutations by exon
dosage methods and bidirectional Sanger sequencing of the entire
coding sequence using an ABI 3730 automated sequencer, as
described previously (Periquet et al, 2003; Ibanez et al, 2006).
Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium
supplemented with glucose (4.5 g/l), L-glutamine (2 mM), HEPES
(10 mM), foetal bovine serum (10%) and penicillin (50 U/ml)/
streptomycin (50 lg/ml) plus 1% (v/v) non-essential amino acid
and grown at 37°C in a 5% CO2 atmosphere.
Isolation and immortalisation of MEFs
Littermate matched wild-type and homozygous PINK1 or Parkin
knockout mouse embryonic fibroblasts (MEFs) were isolated from
mouse embryos at day E13.5 resulting from crosses between
heterozygous mice using a previously described protocol (Castor
et al, 2013). Briefly, on day E13.5, the heads were used for geno-
typing. The red organs were removed, and the embryo was minced
and resuspended in 1 ml trypsin and incubated at 37°C for 15 min
before the addition of 10 ml growth medium. Cells were plated and
allowed to attach overnight before cells were washed with fresh
medium to remove debris. When cells reached confluency, they
were split and replated and this was considered passage 1. MEF cells
were immortalised using SV40 large T antigen. All animal studies
and breeding was approved by the University of Dundee ethical
committee and performed under a U.K. Home Office project licence.
Generation of Rab8A knockout cells using CRISPR/Cas9
gene editing
Analysis of the RAB8A locus (ENSG00000167461) showed a
common translational start in exon 1 and potential KO CRISPR guide
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pairs were subsequently identified using a sanger centre CRISPR
webtool (http://www.sanger.ac.uk/htgt/wge/find_crisprs). The chosen
guide pair (sense 50-TGTTCAAGCTGCTGCTGATC and antisense
50-ATATTACACTCTCTCCCCGA) cut as far upstream as possible to
generate indels in the region containing the ATG start codon; an
additional G was added to the 50 end of each guide to maximize
expression from the U6 promoter. Complementary oligos were
designed and annealed to yield dsDNA inserts with compatible over-
hangs to BbsI-digested vectors (Cong et al, 2013), the antisense
guide was cloned into the spCas9 D10A expressing vector pX335
(Addgene Plasmid #42335) and the sense guide into the puromycin
selectable plasmid pBABED P U6 (University of Dundee). HeLa cells
were co-transfected with 1 lg of each plasmid using PEI in a 10-cm
dish. Following 24 h of recovery and a further 48 h of puromycin
selection (1 lg/ml) the transfection was repeated and cells subjected
to a further round of puromycin selection to enrich for transfectants.
The cell pool was subsequently single cell sorted by FACS and clones
analysed for RAB8A depletion by immunoblotting and sequencing.
Briefly, genomic DNA was isolated and the region surrounding the
ATG start codon of RAB8A amplified by PCR (forward primer:
TCTTCACTGC TGGTCAATCAGAGC; reverse primer: GTGGAGA
TAAAAGTGGAG TTGAAGGC). The resulting PCR products were
subcloned into the holding vector pSC-B (StrataClone Blunt PCR
Cloning Kit, Agilent Technologies) and twelve colonies (white) picked
for each clonal line. Plasmid DNAs were isolated and cut with EcoRI
to verify insert size before being sent for sequencing with primers
M13F and M13R. PCR products are mixed following CRISPR due to
differences between the targeted alleles and we have found in prac-
tice that analysis of >10 clones from a given clonal line is sufficient to
verify the allelic population. Sequencing of the exon 1 PCR fragments
from the knockout lines revealed a 110 base-pair deletion (including
start codon) and 70 base-pair insertion (34 + 36 base-pair insertions)
confirming the presence of frameshifting indels and successful KO of
the RAB8A loci (data not shown).
SILAC experiment and phosphopeptide enrichment
Flp-In T-Rex HEK293 cells stably expressing either FLAG empty,
PINK1-FLAG kinase-inactive or PINK1-FLAG wild-type were grown
in “light” (K0R0), “medium” (K4R6) and “heavy” (K8R10) SILAC
media, respectively, for at least 5 passages. Cells in each condition
were stimulated with 10 lM CCCP for 3 h and were scraped in
appropriate amount of homogenisation buffer (8.55% w/v sucrose
in 3 mM imidazole pH 7.4, supplemented with protease inhibitor
and phosphatase inhibitor cocktail from Roche and Benzonase from
Roche). The cells were lysed by mechanical disruption using a stain-
less steel homogeniser, and unbroken cells and nuclei were
removed by centrifugation at 1,000 g for 10 min at 4°C. The
membrane fraction in the remaining post-nuclear supernatant was
enriched by ultra-centrifugation at 100,000 g for 30 min (4°C). Four
biological replicates of 3 mg of these membrane fractions enriched
in mitochondria were solubilised in 1% sodium 3-[(2-methyl-2-
undecyl-1,3-dioxolan-4-yl)methoxy]-1-propanesulfonate (commer-
cially available as RapiGest, Waters, UK), 50 mM Tris pH 8.0 and
1 mM TCEP plus phosphatase inhibitors and heated for 5 min at
70°C. After alkylation with 5 mM iodoacetamide and subsequent
quenching with 10 mM DTT, solutions were diluted to 0.1% Rapi-
Gest using 50 mM Tris–HCl pH 8.0 and proteins were digested by
trypsin (1:50) overnight at 37°C. Rapigest was cleaved by the addi-
tion of 1% trifluoroacetic acid (TFA) and removed by solid-phase
extraction. Samples were then resolubilised in 80% acetonitrile
(ACN) and 0.1% formic acid and subjected to HILIC (hydrophilic
interaction chromatography) (McNulty & Annan, 2008) using a TSK
gel Amide-80 (4.6 mm × 25 cm) column (Tosoh, Japan). Fifteen of
the later fractions, which contain the phosphopeptides, were
collected in 2-min intervals and subsequently enriched for phospho-
peptides using self-made TiO2 spin columns (Trost et al, 2009).
LC-MS/MS protein identification and quantitation
Mass spectrometric analyses were conducted similarly as previously
described (Ritorto et al, 2013; Dill et al, 2015) on an Orbitrap Velos
Pro mass spectrometer coupled to an Ultimate 3000 UHPLC
system with a 50 cm Acclaim PepMap 100 analytical column
(75 lm ID, 3 lm C18) in conjunction with a PepMap trapping
column (100 lm × 2 cm, 5 lm C18) (all Thermo-Fisher Scientific).
Acquisition settings were as follows: lockmass of 445.120024, MS1
with 60,000 resolution, top 20 CID MS/MS using Rapid Scan,
monoisotopic precursor selection, unassigned charge states and
z = 1 rejected, and dynamic exclusion of 60 s with repeat count 1.
Normalised collision energy was set to 35, and activation time was
10 ms. Four-hour linear gradients were performed from 5% solvent
B to 35% solvent B (solvent A: 0.1% formic acid, solvent B: 80%
acetonitrile 0.08% formic acid) at 300 nl/min in 217 min with a
23-min washing and re-equilibration step.
Protein identification and quantification were made using
MaxQuant (Cox & Mann, 2008) version 1.3.0.5 with the following
parameters: FT mass tolerance 20 ppm; MS/MS ion trap tolerance
0.5 Da; trypsin/P set as enzyme; stable modification carbamido-
methyl (C); variable modifications, oxidation (M), acetyl (protein
N-term) and phospho (STY); maximum 5 modifications per peptide;
and 2 missed cleavages. Searches were conducted using a combined
UniProt-Trembl Homo sapiens database with isoforms downloaded
on 15 February 2012 plus common contaminants (117,706
sequences). Identifications were filtered at a 1% FDR at the peptide
level, accepting a minimum peptide length of 7. Quantification
required a minimum ratio count of 2. Requantification was enabled,
and match between runs was allowed within a 5-min window.
Normalised ratios for peptides showed a median variability of 25–28%
(ratio variation for 95% of the ratios was below 75%). Downstream
analyses were performed in Perseus 1.4.0.20 (Cox & Mann, 2012)
where statistical tests (one-sample t-test, P < 0.05) for each ratio (H/L,
H/M, M/L) were performed. The mass spectrometry raw data and the
Maxquant output from this publication have been submitted to the
PRIDE database (Vizcaino et al, 2013) (https://www.ebi.ac.uk/pride/
archive/) and assigned the identifier PXD002127.
LC-MS/MS mapping of in-gel tryptic digested Rab8A, 8B and 13
Ser111 phosphopeptides
Samples were analysed on a linear ion trap–orbitrap hybrid
mass spectrometer (Orbitrap-Classic, Thermo) equipped with a
nano-electrospray ion source (Thermo) and coupled to a Proxeon
EASY-nLC system. Peptides were injected onto a Thermo (Part No.
160321) Acclaim PepMap100 reversed-phase C18 3 lm column,
75 lm × 15 cm, with a flow of 300 nl/min, and eluted with a
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45-min linear gradient of 95% solvent A (2% acetonitrile, 0.1%
formic acid in H2O) to 40% solvent B (90% acetonitrile, 0.08%
formic acid in H2O), followed by a rise to 80% solvent B at 48 min.
The instrument was operated with the “lock mass” option to
improve the mass accuracy of precursor ions, and data were
acquired in the data-dependent mode, automatically switching
between MS and MS-MS acquisition. Full-scan spectra (m/z 340–
2,000) were acquired in the orbitrap with resolution R = 60,000 at
m/z 400 (after accumulation to an FTMS Full AGC Target;
1,000,000; MSn AGC Target; 100,000). The 5 most intense ions,
above a specified minimum signal threshold (5,000), based upon a
low resolution (R = 15,000) preview of the survey scan, were frag-
mented by collision-induced dissociation and recorded in the linear
ion trap (Full AGC Target: 30,000; MSn AGC Target: 5,000). Multi-
stage activation was used to provide a pseudo MS3 scan of any
parent ions showing a neutral loss of 48.9885, 32.6570 and 24.4942,
allowing for 2+ , 3+ and 4+ ions respectively. The resulting pseudo
MS3 scan was automatically combined with the relevant MS2 scan
prior to data analysis. Extracted ion chromatograms (XICs) were
obtained using Xcalibur software (Thermo). Automatic processing
was employed with parameters as follows: Gaussian smoothing, 7
points; no baseline subtraction; mass tolerance  10.0 ppm; and
mass precision, 4 decimals.
Immunoblotting and immunoprecipitation
Protein lysates were extracted in lysis buffer containing buffers
50 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% (w/v)
Triton, 1 mM sodium orthovanadate, 10 mM sodium glycerophos-
phate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate,
0.25 M sucrose, 0.1% (v/v) 2-mercaptoethanol, 1 mM benza-
midine, 0.1 mM PMSF and protease inhibitor cocktail (Roche).
Lysates were clarified by centrifugation at 17,000 g for 15 min at
4°C, and the supernatant was collected. Protein concentration was
determined using the Bradford method (Thermo Scientific) with
BSA as the standard.
For immunoprecipitation of HA-tagged Rab proteins, 0.25–1 mg
of protein extracts was undertaken by standard methods with anti-
HA agarose beads. For immunoprecipitation of endogenous Rab8A,
cell lysates containing 1 mg of protein were immunoprecipitated at
4°C for at least 2 h with 2 ll of anti-Rab8A antibody pre-bound to
15 ll of protein A agarose beads. The immunoprecipitates were
washed three times with lysis buffer containing 0.15 M NaCl and
eluted by resuspending in 20 ll of 1× SDS sample buffer.
Immunoprecipitates or cell extracts (25–50 lg of protein) were
subjected to SDS–PAGE (4–12%) and transferred on to nitrocellu-
lose membranes. Membranes were blocked for 1 h in Tris-buffered
saline with 0.1% Tween (TBST) containing 5% (w/v) BSA.
Membranes were probed with the indicated antibodies in TBST
containing 5% (w/v) BSA overnight at 4°C. Detection was
performed using appropriate HRP-conjugated secondary antibodies
and enhanced chemiluminescence reagent.
Mitochondrial protein enrichment and ubiquitylated
mitochondrial protein capture
Mitochondrial proteins were enriched as described previously
(Kazlauskaite et al, 2015). For ubiquitylated protein capture, 200 lg
of mitochondrial protein extracts was used for pull down with
HALO-UBAUBQLN1 resin as described previously (Kazlauskaite et al,
2015).
Structural and bioinformatics analysis
Phosphorylation sites
Full-length protein sequences for ubiquitin, Parkin, Rab1A and
Rab8A were retrieved from UniProt via the EMBL-EBI database
retrieval service (Lopez et al, 2003), client with the Jalview Desktop
(Waterhouse et al, 2009) and manually aligned to match observed
phosphorylation site positions. Representative structures for phos-
phorylated regions were identified via UniProt annotation and the
PDBe SIFTS service (Velankar et al, 2013), and structures for ubiq-
uitin (PDB code: 2W9N chain A), Parkin (PDB code: 1IYF model 1
chain A), Rab1A (PDB code: 3TKL chain A) and Rab8A (PDB code:
4LXH chain A) were downloaded. Structures were visualised in
UCSF Chimera (Pettersen et al, 2004) and were superimposed with
UCSF Chimera’s match command using the C-a positions for the
observed site and adjacent two amino acids on either side. Detailed
descriptions of local secondary structure conformations at these
locations were obtained from PDBsum (de Beer et al, 2014), and the
visualisation was rendered with POVray (bundled with UCSF
Chimera).
Human and Yeast Rab8 GTPases and GEFs
Multiple sequence alignment of yeast Ypt1, yeast Sec4 and human
Rab8A was made with T-COFFEE (default settings, v8.99). Align-
ment of the yeast Sec2 and human Rabin8 sequences was performed
with Jalview’s pairwise alignment function. Alignment of PDB struc-
tures containing Ypt1, Sec4 and Rab8A was made with UCSF
Chimera’s matchmaker function (v 1.10.1 with default parameters).
Kinase assays and phosphorylation site mapping
For in vitro kinase assay, 1.2 lg of recombinant WT or S111A
mutant Rab8A, or 0.5 lg of ubiquitin as a positive control was incu-
bated with 1.1 lg of E. coli-expressed WT or KI (D359A) MBP-fused
TcPINK1 in total 10 ll of kinase buffer containing 50 mM Tris/HCl
(pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT and 0.1 mM
[c-32P] ATP (approx. 500 cpm/pmol) at 30°C with continuous shak-
ing. Reactions were terminated by adding SDS sample buffer at the
time indicated. The reaction mixtures were then resolved by SDS–
PAGE. Proteins were detected by colloidal Coomassie blue staining
and dried completely using a gel dryer (Bio-Rad Laboratories).
Incorporation of [c-32P] into substrates was analysed by autoradiog-
raphy using Amersham hyper-sensitive film. Cerenkov counting
was used to calculate the stoichiometry of substrate phosphoryla-
tion as mol of [c-32P] incorporation/mol of substrate.
For mapping the site on Rab8A phosphorylated by TcPINK1,
recombinant Rab8A (24 lg) was incubated with MBP-fused WT
TcPINK1 (50 lg) for 120 min in the same condition as the kinase
assay, except [c-32P] ATP that was approx. 20,000 cpm/pmol. The
reaction was terminated by the addition of SDS sample buffer with
10 mM DTT, boiled and subsequently alkylated with 50 mM iodo-
acetamide before samples were subjected to electrophoresis on a
Bis-Tris 4–12% polyacrylamide gel, which was then stained with
colloidal Coomassie blue (Invitrogen). Protein bands were excised
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from the gel, and 98% of the 32P radioactivity incorporated into
Rab8A was recovered from the gel bands after tryptic digestion.
Peptides were chromatographed on a reversed-phase HPLC Vydac
C18 column (catalogue number 218TP5215, Separations Group)
equilibrated in 0.1% trifluoroacetic acid, and the column developed
with a linear acetonitrile gradient at a flow rate of 0.2 ml/min before
fractions (0.1 ml each) was collected and analysed for 32P radioactiv-
ity by Cerenkov counting. Isolated phosphopeptides were analysed
by LC–MS/MS on a Thermo U3000 RSLC nano-LC system coupled to
a Thermo LTQ-Orbitrap Velos Pro mass spectrometer. The resultant
data files were searched using Mascot (www.matrixscience.com)
run on an in-house system against a database containing the Rab8A
sequence, with a 10 ppm mass accuracy for precursor ions and a
0.6 Da tolerance for fragment ions and allowing for phospho (S/T),
phospho (Y), oxidation (M) and dioxidation (M) as variable modifi-
cations. Individual MS/MS spectra were inspected using Xcalibur
v2.2 software (Thermo Scientific). The site of phosphorylation of
these 32P-labelled peptides was determined by solid-phase Edman
degradation on a Shimadzu PPSQ33A sequencer of the peptide
coupled to Sequelon-AA membrane (Applied Biosystems).
Protein expression and purification
The wild-type (WT) or kinase-inactive Tribolium castaneum PINK1
(TcPINK1) was expressed in E. coli and purified as described previ-
ously (Woodroof et al, 2011). The Rab8A WT was expressed in
E. coli BL21(DE3) and purified as described previously (Bleimling
et al, 2009). The S111E and S111A substitutions of Rab8A were
introduced by site-directed mutagenesis (QuikChange, Agilent
Technologies, Santa Clara, CA, USA), and proteins were expressed
and purified analogously to Rab8A WT. The expression and purifi-
cation of the Rabin8153–237 and OCRL1539–901 were performed as
described in the study by Guo et al (2013) and Hou et al (2011).
His-halo-ubiquilin1 UBA domain tetramer (UBAUBQLN1) was
expressed in E. coli BL21 cells and purified as described previously
(Kazlauskaite et al, 2015).
Analytical size-exclusion chromatography
OCRL1539–901 (15 lM) and individual Rab proteins (19.5 lM) were
incubated for 1 h in a volume of 70 ll and subjected to chromato-
graphic separation on a Superdex 200 (10/30) gel filtration
column (GE Healthcare, USA) using a HPLC system (Shimadzu,
Japan) equipped with a SPD-20AV UV/Vis detector and detected
at 254 nm. The column was pre-equilibrated with 20 mM HEPES
pH 7.5, 50 mM NaCl, 2 mM DTE, 1 mM MgCl2 and 1 lM
GppNHp.
Rabin8 catalysed nucleotide exchange assay
The Rab8A-GDP variants were loaded with the fluorescent GDP
analogue 20/30-(N-methylanthraniloyl)-GDP (mantGDP). The loading
was performed with 5-fold excess over the protein of mantGDP in
the presence of 5 mM EDTA for 2 h at room temperature in the
dark. Rabin8-catalysed mantGDP release was measured at 25°C with
a Fluoromax-4 fluorescence spectrometer (HORIBA Jobin Yvon),
excited at kexc = 365 nm and monitored at kem = 440 nm. The
Rab proteins (1 lM) were incubated with 100 lM GDP in 1 ml
buffer (20 mM HEPES pH 7.5, 50 mM NaCl, 1 mM MgCl2, 2 mM
DTE) in a Quartz SUPRASIL cuvette (Hellma Analytics, Germany),
and the reaction was started by the addition of 0.5 lM Rabin8. The
decrease in mant fluorescence was used as a measure of mantGDP
release.
Thermal shift assay
The thermal shift assay can be used to investigate the stability of
proteins (Ericsson et al, 2006). The melting point of the protein
is determined by the fluorescence of a dye (Sypro Orange,
Sigma-Aldrich, USA). The fluorescence of the dye is quenched in
solution but remains when the dye is bound to hydrophobic regions.
Through a successive increase in temperature, the protein unfolds
and exposes more hydrophobic regions that the dye can bind to.
This leads to an increase in fluorescence. The assay was performed
with 1 and 10 lg of the Rab proteins, respectively. The proteins
were mixed in a 1:1 ration with a 10× Sypro Orange solution in a
total volume of 20 ll. The probes were prepared as triplicates, and
the assay was performed in a 96-well plate in a RT–PCR cycler
(Agilent Technologies Stratagene Mx3000P).
Intrinsic GTP hydrolysis
The Rab proteins (1 mg) were loaded with GTP by incubation with
a 20-fold excess of GTP and 5 mM EDTA for 2 h at RT. After the
loading, excess GTP was removed by applying the protein solution
to a Nap10 column (GE Healthcare, USA) and subsequent washing
with buffer (20 mM HEPES pH 7.5, 50 mM NaCl, 1 lM GTP, 2 mM
DTE) according to the manufacturer’s manual. The analysis of
intrinsic GTP hydrolysis was performed with 50 lM protein. At
defined time points, 20 ll of the protein solution was denatured by
incubation for 10 min at 95°C and subsequently centrifuged to sepa-
rate the protein and the nucleotide. An isocratic elution (50 mM
potassium phosphate, pH 6.6, 10 mM tetra-N-butylammonium
bromide, 12% (v/v) acetonitrile) was used to separate GDP and
GTP on a Prontosil C18 120-5-C18-AQ column (Bischoff chromato-
graphy). The peak areas of GTP and GDP were used as a measure of
GTP hydrolysis.
Rab-GAP assay
Rab8 proteins (1 mg) were loaded with GTP by incubation with a
20-fold excess of GTP and 5 mM EDTA for 2 h at RT. After the
loading, excess GTP was removed by applying the protein solution
to Nap10 columns (GE Healthcare, USA) and subsequent washing
with buffer (20 mM HEPES pH 7.5, 50 mM NaCl, 1 lM GTP,
2 mM DTE) according to the manufacturer’s manual. The analysis
of the GAP-stimulated GTP hydrolysis was performed with 30 lM
of the respective Rab8 variant and 100 nM of TBC1D20. At defined
time points, 20 ll of the protein solution was denatured by incuba-
tion for 10 min at 95°C and subsequently centrifuged to separate
the protein and the nucleotide. An isocratic elution (50 mM potas-
sium phosphate, pH 6.6, 10 mM tetra-N-butylammonium bromide,
12% (v/v) acetonitrile) was used to separate GDP and GTP on a
Prontosil C18 120-5-C18-AQ column (Bischoff chromatography).
The peak areas of GTP and GDP were used as a measure of GTP
hydrolysis.
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